WO2000024782A3 - Modified peptides, comprising an fc domain, as therapeutic agents - Google Patents

Modified peptides, comprising an fc domain, as therapeutic agents Download PDF

Info

Publication number
WO2000024782A3
WO2000024782A3 PCT/US1999/025044 US9925044W WO0024782A3 WO 2000024782 A3 WO2000024782 A3 WO 2000024782A3 US 9925044 W US9925044 W US 9925044W WO 0024782 A3 WO0024782 A3 WO 0024782A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
domain
therapeutic agents
display
biologically active
Prior art date
Application number
PCT/US1999/025044
Other languages
French (fr)
Other versions
WO2000024782A2 (en
Inventor
Ulrich Feige
Chuan-Fa Liu
Janet Cheetham
Thomas Charles Boone
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26802505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000024782(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CNB998147273A priority Critical patent/CN1310948C/en
Priority to BR9914708-4A priority patent/BR9914708A/en
Priority to EP99971003A priority patent/EP1144454B2/en
Priority to KR1020077006961A priority patent/KR100753305B1/en
Priority to CA2347131A priority patent/CA2347131C/en
Priority to IL14236599A priority patent/IL142365A0/en
Priority to MXPA01003873A priority patent/MXPA01003873A/en
Priority to DE69937752T priority patent/DE69937752T3/en
Priority to HU0203506A priority patent/HU229485B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to DK99971003.1T priority patent/DK1144454T4/en
Priority to KR1020077006958A priority patent/KR100753304B1/en
Priority to NZ510888A priority patent/NZ510888A/en
Priority to JP2000578351A priority patent/JP2003512011A/en
Priority to EA200100464A priority patent/EA005404B1/en
Priority to AU12322/00A priority patent/AU767725B2/en
Priority to SI9930999T priority patent/SI1144454T2/en
Priority to ES99971003T priority patent/ES2299278T5/en
Priority to SK525-2001A priority patent/SK287037B6/en
Publication of WO2000024782A2 publication Critical patent/WO2000024782A2/en
Priority to IL142365A priority patent/IL142365A/en
Priority to NO20011963A priority patent/NO331733B1/en
Priority to BG105461A priority patent/BG65721B1/en
Priority to HK02102701.4A priority patent/HK1042097B/en
Publication of WO2000024782A3 publication Critical patent/WO2000024782A3/en
Priority to AU2004200687A priority patent/AU2004200687C1/en
Priority to AU2004200691A priority patent/AU2004200691C9/en
Priority to AU2004200690A priority patent/AU2004200690C1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
PCT/US1999/025044 1998-10-23 1999-10-25 Modified peptides, comprising an fc domain, as therapeutic agents WO2000024782A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
NZ510888A NZ510888A (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
JP2000578351A JP2003512011A (en) 1998-10-23 1999-10-25 Modified peptides as therapeutics
EP99971003A EP1144454B2 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
KR1020077006961A KR100753305B1 (en) 1998-10-23 1999-10-25 A composition of compound comprising modified peptides as therapeutic agents and process for preparing this compound
CA2347131A CA2347131C (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
IL14236599A IL142365A0 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
MXPA01003873A MXPA01003873A (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents.
DE69937752T DE69937752T3 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
HU0203506A HU229485B1 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
BR9914708-4A BR9914708A (en) 1998-10-23 1999-10-25 Composition of matter, DNA, expression vector, host cell, and, process for preparing a pharmacologically active compound
DK99971003.1T DK1144454T4 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
KR1020077006958A KR100753304B1 (en) 1998-10-23 1999-10-25 A composition of compound comprising modified peptides as therapeutic agents and process for preparing this compound
EA200100464A EA005404B1 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
CNB998147273A CN1310948C (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
SK525-2001A SK287037B6 (en) 1998-10-23 1999-10-25 Modified peptide and the use thereof, DNA, expression vector, host cell, pharmaceutical composition, and a method of preparing the pharmacologically active compound
AU12322/00A AU767725B2 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
SI9930999T SI1144454T2 (en) 1998-10-23 1999-10-25 Modified peptides as therapeutic agents
ES99971003T ES2299278T5 (en) 1998-10-23 1999-10-25 Modified peptides that act as therapeutic agents
IL142365A IL142365A (en) 1998-10-23 2001-04-02 Tpo mimetic peptides linked to an fc domain protein
NO20011963A NO331733B1 (en) 1998-10-23 2001-04-20 Compound with Modified Peptides, DNA, Expression Vector, Host Cell and Pharmaceutical Preparation, Use of the Compounds and Methods of Preparing a Pharmacologically Active Compound
BG105461A BG65721B1 (en) 1998-10-23 2001-04-24 Modified peptides as therapeutic agents
HK02102701.4A HK1042097B (en) 1998-10-23 2002-04-10 Modified peptides as therapeutic agents
AU2004200687A AU2004200687C1 (en) 1998-10-23 2004-02-20 Modified peptides as therapeutic agents
AU2004200691A AU2004200691C9 (en) 1998-10-23 2004-02-20 Modified peptides as therapeutic agents
AU2004200690A AU2004200690C1 (en) 1998-10-23 2004-02-20 Modified peptides as therapeutic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10537198P 1998-10-23 1998-10-23
US60/105,371 1998-10-23
US09/428,082 US6660843B1 (en) 1998-10-23 1999-10-22 Modified peptides as therapeutic agents
US09/428,082 1999-10-22

Publications (2)

Publication Number Publication Date
WO2000024782A2 WO2000024782A2 (en) 2000-05-04
WO2000024782A3 true WO2000024782A3 (en) 2002-06-06

Family

ID=26802505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025044 WO2000024782A2 (en) 1998-10-23 1999-10-25 Modified peptides, comprising an fc domain, as therapeutic agents

Country Status (29)

Country Link
US (7) US6660843B1 (en)
EP (1) EP1144454B2 (en)
JP (9) JP2003512011A (en)
KR (3) KR100753303B1 (en)
CN (8) CN1781946A (en)
AT (1) ATE380828T1 (en)
AU (3) AU767725B2 (en)
BG (1) BG65721B1 (en)
BR (1) BR9914708A (en)
CA (1) CA2347131C (en)
CY (1) CY1107881T1 (en)
CZ (1) CZ304242B6 (en)
DE (1) DE69937752T3 (en)
DK (1) DK1144454T4 (en)
EA (1) EA005404B1 (en)
ES (1) ES2299278T5 (en)
HK (2) HK1042097B (en)
HU (1) HU229485B1 (en)
IL (2) IL142365A0 (en)
MX (1) MXPA01003873A (en)
NO (1) NO331733B1 (en)
NZ (2) NZ510888A (en)
PL (1) PL211164B1 (en)
PT (1) PT1144454E (en)
RS (1) RS51852B (en)
SI (1) SI1144454T2 (en)
SK (1) SK287037B6 (en)
WO (1) WO2000024782A2 (en)
ZA (1) ZA200102753B (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US8410051B2 (en) 2008-06-04 2013-04-02 Amgen Inc. FGF21 mutants and uses thereof
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity

Families Citing this family (528)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE69934425T2 (en) * 1998-10-23 2007-09-27 Amgen Inc., Thousand Oaks THROMBOPOIETIN SUBSTITUTE
AU2880400A (en) * 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
ES2433678T3 (en) * 1999-03-03 2013-12-12 Eli Lilly & Company Pharmaceutical formulations of echinocandin containing micelle-forming surfactants
PT1157030E (en) * 1999-03-03 2004-01-30 Lilly Co Eli EQUINOCANDINE / CARBON HYDRATE COMPLEXES
JP2003503426A (en) 1999-07-02 2003-01-28 ジェネンテック・インコーポレーテッド FVIIa antagonist
DE60028970T2 (en) 1999-07-02 2007-02-15 Genentech Inc., San Francisco AT HER2 BINDING PEPTIDE COMPOUNDS
NZ517184A (en) * 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001009165A2 (en) * 1999-07-29 2001-02-08 The Johns Hopkins University ACTIVATION OF PEPTIDE PRODRUGS BY hK2
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001081376A2 (en) * 2000-04-21 2001-11-01 Amgen Inc. Apo-ai/aii peptide derivatives
EP1278778A2 (en) * 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
CA2408617A1 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
NZ522924A (en) * 2000-05-26 2004-12-24 Ortho Mcneil Pharm Inc Neuroprotective peptides
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
MXPA02011891A (en) * 2000-06-02 2004-04-02 Eidgenoess Tech Hochschule Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds.
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
EP1317536B1 (en) * 2000-09-05 2009-05-13 Amgen Inc. Tnf receptor-like molecules and uses thereof
ES2380367T3 (en) * 2000-12-05 2012-05-11 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7491702B2 (en) * 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
US7622446B2 (en) * 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
EE05294B1 (en) 2001-05-11 2010-04-15 Amgen Inc. TALL-1 binding agent composition
ES2674888T3 (en) * 2001-06-26 2018-07-04 Amgen Inc. OPGL antibodies
DE60232742D1 (en) 2001-10-04 2009-08-06 Immunex Corp UL16 BINDING PROTEIN 4
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20030113270A1 (en) * 2001-12-14 2003-06-19 Clark Abbot F. Vasoactive intestinal peptides for glaucomatous retinopathy
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) * 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
DE10209822A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
ES2557741T3 (en) 2002-03-27 2016-01-28 Immunex Corporation Procedures to increase polypeptide production
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
WO2004002417A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
EP1394180B1 (en) * 2002-08-06 2008-07-16 AplaGen GmbH Synthetic mimetic molecules of physiological binding molecules
CN1675243A (en) * 2002-08-06 2005-09-28 阿普拉根有限责任公司 Binding molecules
PL376536A1 (en) 2002-08-28 2006-01-09 Immunex Corporation Compositions and methods for treating cardiovascular disease
EP2213685B1 (en) 2002-09-06 2013-11-27 Amgen Inc. Therapeutic anti-IL-1R1 monoclonal antibody
CN100348618C (en) 2002-09-11 2007-11-14 弗雷泽纽斯卡比德国有限公司 Process for producing hydroxyalkyl starch derivatives
AU2003275077B2 (en) 2002-09-18 2010-02-04 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
ES2562177T3 (en) 2002-09-27 2016-03-02 Xencor Inc. Optimized Fc variants and methods for their generation
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
DK1558643T3 (en) * 2002-11-09 2009-09-07 Immunocore Ltd Cell receptor presentation
MEP57508A (en) * 2002-12-20 2011-05-10 Amgen Inc Binding agents which inhibit myostatin
US7125849B2 (en) * 2003-01-14 2006-10-24 The Scripps Research Institute Peptide-based angiogenesis inhibitors and methods of use thereof
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
RU2005127668A (en) * 2003-02-06 2006-01-27 Мерк Патент ГмбХ (DE) PEPTIDE SULFONAMIDES
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20050281829A1 (en) * 2003-05-06 2005-12-22 Hehir Cristina A T Fc chimeric proteins with anti-HIV drugs
ATE497783T1 (en) * 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc CLOTTING FACTOR VII-FC CHIMERIC PROTEINS FOR THE TREATMENT OF HEMOSTATIC DISEASES
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050037947A1 (en) * 2003-05-06 2005-02-17 Bitonti Alan J. Inhibition of drug binding to serum albumin
WO2004101606A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
KR101227666B1 (en) * 2003-05-12 2013-01-31 아피맥스, 인크. Peptides that bind to the erythropoietin receptor
EP2204193A3 (en) * 2003-05-12 2010-08-18 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
US7485312B2 (en) * 2003-06-20 2009-02-03 Dade Behring Marburg Gmbh Surface protein (HBsAg) variant of the hepatitis B virus
TW201319088A (en) 2003-07-18 2013-05-16 Amgen Inc Specific binding agents to hepatocyte growth factor
ATE554108T1 (en) 2003-07-25 2012-05-15 Amgen Inc PROCEDURES REGARDING LDCAM AND CRTAM
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7256038B2 (en) * 2003-08-18 2007-08-14 Regents Of The University Of California Polypeptide display libraries and methods of making and using thereof
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2304069B1 (en) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. PEPTIDES ABLE TO JOIN THE TRANSFORMING FACTOR OF BETA 1 GROWTH (TGF-B1).
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005081687A2 (en) * 2003-09-30 2005-09-09 Centocor, Inc. Human hinge core mimetibodies, compositions, methods and uses
UA89481C2 (en) * 2003-09-30 2010-02-10 Центокор, Инк. Human epo mimetic hinge core mimetibodies, compositions, methods and uses
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
KR20050047030A (en) * 2003-11-13 2005-05-19 한미약품 주식회사 Igg fc fragment for a drug carrier and method for the preparation thereof
US20110160440A1 (en) 2003-12-12 2011-06-30 Genencor International, Inc. Cab Molecules
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
WO2005092928A1 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
ES2390885T3 (en) * 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkylamidone and a protein
CA2557910C (en) * 2004-04-02 2012-05-29 Amgen Inc. Methods of reducing aggregation of il-1ra
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
EP1735350B1 (en) 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
JP2005309295A (en) * 2004-04-26 2005-11-04 Nec Corp Element, device, and system for optical amplification
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
JP2008505119A (en) 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション Macromolecule-Factor IX Conjugate
MX2007000216A (en) * 2004-07-08 2007-03-15 Amgen Inc Therapeutic peptides.
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
ME00226B (en) 2004-07-15 2011-02-10 Medarex Llc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
DK1797127T3 (en) * 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006052493A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
CN101142234A (en) * 2004-11-11 2008-03-12 阿费麦克斯公司 Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20070110760A1 (en) * 2005-01-14 2007-05-17 Monroe John G Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
US8053415B2 (en) * 2005-01-21 2011-11-08 Washington University In St. Louis Compounds having RD targeting motifs
US20090202619A1 (en) * 2005-02-18 2009-08-13 The University Of Tokushima Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
DK1877102T3 (en) 2005-04-28 2014-07-21 Danisco Us Inc TAB MOLECULES
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP2008543839A (en) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド Self-buffering protein formulation
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
CA2648732A1 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
CN101379085B (en) * 2005-06-30 2013-03-27 Abbvie公司 IL-12/P40 binding proteins
EP2397496A3 (en) 2005-07-18 2013-05-29 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
SI2298815T1 (en) * 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
UA97628C2 (en) * 2005-08-16 2012-03-12 Ханми Холдингз Ко., Лтд. Method For the Mass Production of Immunoglobulin Fc Region Deleted Initial Methionine Residues
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
KR100780405B1 (en) * 2005-08-31 2007-11-28 재단법인서울대학교산학협력재단 A Process for screening of a binding peptides specific for specific RNA and RNA binding peptides therefrom
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
US8445642B1 (en) * 2005-10-13 2013-05-21 The United States Of America As Represented By The Secretary Of Agriculture Methods to differentiate protein conformers
JP5905184B2 (en) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． Methods and compositions for use in treating patients with autoantibody positive disease
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
KR20080071134A (en) * 2005-10-24 2008-08-01 센토코 인코포레이티드 Glp-2 mimetibodies, polypeptides, compositions, methods and uses
SI2500360T1 (en) * 2005-10-31 2015-11-30 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
KR20180058863A (en) 2005-11-30 2018-06-01 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
CA2856436A1 (en) * 2005-12-06 2007-06-14 Amgen Inc. Uses of myostatin antagonists
WO2007067564A2 (en) 2005-12-08 2007-06-14 Amgen Inc. Improved host cells and culture methods
PE20100748A1 (en) 2005-12-12 2010-11-12 Hoffmann La Roche ANTI BETA-4-AMYLOID ANTIBODY CONTAINING GLYCOSYLATED ASPARAGINE IN THE VARIABLE REGION OF VH
US20090054763A1 (en) * 2006-01-19 2009-02-26 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
US9012605B2 (en) * 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
AR059066A1 (en) 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US20070179094A1 (en) 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US8293500B2 (en) 2006-03-22 2012-10-23 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
CA2648035A1 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia
US10167332B2 (en) 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DK2007885T3 (en) * 2006-04-11 2010-11-08 Csl Behring Gmbh Method for enhancing the in vivo recovery of therapeutic polypeptides
JO3324B1 (en) 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
JP2009537145A (en) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション Compositions and methods associated with CD47 for treating immunological diseases and disorders
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
MY188368A (en) 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
MX2009002522A (en) * 2006-09-08 2009-06-19 Genentech Inc Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders.
JP5577543B2 (en) 2006-09-08 2014-08-27 アムジエン・インコーポレーテツド IL-1 family variant
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
EP2061489A4 (en) * 2006-09-15 2009-12-23 Burnham Inst High affinity ephb receptor binding compounds and methods of use thereof
KR20090071598A (en) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 Treatment of liver disorders by administration of receptor-associated protein(rap)-conjugates
US20100297218A1 (en) * 2006-09-20 2010-11-25 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
AR063384A1 (en) 2006-10-25 2009-01-28 Amgen Inc THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
US20080123083A1 (en) * 2006-11-29 2008-05-29 The Regents Of The University Of Michigan System and Method for Photoacoustic Guided Diffuse Optical Imaging
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP5220025B2 (en) * 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド Combination therapy to treat fibrotic diseases
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
KR100888022B1 (en) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion Proteion of Imunoglobulin Fc and Human Apolipoproteina Kringle Fragment
EP2097096B1 (en) * 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
JP2010520855A (en) 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
US8283319B2 (en) * 2007-02-12 2012-10-09 Csl Behring Gmbh Therapeutic application of Kazal-type serine protease inhibitors
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
TWI454479B (en) 2007-03-06 2014-10-01 Amgen Inc Variant activin receptor polypeptides and uses thereof
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
DK2208737T3 (en) 2007-05-03 2017-09-18 Lysomab Gmbh Complement factor H-derived short-consensus repeat antibody constructs
CA2687117A1 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
EP2165716B1 (en) * 2007-06-05 2014-11-12 Oriental Yeast Co., Ltd. Novel bone mass increasing agent
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
SI2489731T1 (en) 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modified lecithin-cholesterol acyltransferase enzymes
US8067548B2 (en) * 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
WO2009014726A1 (en) * 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
EA201070231A1 (en) * 2007-08-09 2010-10-29 Синтоникс Фармасьютикалз, Инк. IMMUNOMODULATING PEPTIDES
JP2010536786A (en) * 2007-08-17 2010-12-02 アムジエン・インコーポレーテツド Preparation of antibody and FC fusion molecule using polycation
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
US20100291086A1 (en) * 2007-09-11 2010-11-18 Christopher Hovens Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
WO2009043049A2 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
KR20100094453A (en) * 2007-10-02 2010-08-26 포텐시아 팔마큐티칼스, 인크. Sustained delivery of compstatin analogs from gels
US7829735B2 (en) 2007-10-26 2010-11-09 Northwestern University Universal phosphoramidite for preparation of modified biomolecules and surfaces
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc Fc variants with altered binding to fcrn
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
JP5701064B2 (en) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド Ferroportin antibody and method of use thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
CN101518644B (en) * 2008-02-26 2011-07-13 上海交通大学医学院附属第九人民医院 Application of Ang-2 and genes thereof in pharmacy
CN101965200B (en) * 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 Conjugated factor VIII molecules
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
ES2487846T3 (en) 2008-05-01 2014-08-25 Amgen, Inc. Anti-hepcindin antibodies and methods of use
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2009136382A2 (en) * 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
WO2009142460A2 (en) * 2008-05-23 2009-11-26 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
JP2011523853A (en) 2008-06-03 2011-08-25 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
KR20110016959A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
KR101648734B1 (en) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
TWI388570B (en) 2008-07-23 2013-03-11 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2168590A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
CN103002911B (en) 2008-09-26 2015-08-26 昂考梅德药品有限公司 FZ is in conjunction with medicament and application thereof
PE20150680A1 (en) 2008-11-26 2015-05-16 Amgen Inc VARIANTS OF ACTIVIN IIB RECEPTOR POLYPEPTIDES AND APPLICATIONS OF THEM
US20120121537A1 (en) * 2009-01-12 2012-05-17 Chaomin Sun Methods and Compositions for Inhibiting Hepatitis C Virus Replication
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
RU2011135768A (en) * 2009-01-29 2013-03-10 Эбботт Лэборетриз PROTEINS BINDING IL-1
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
PE20121094A1 (en) 2009-03-05 2012-09-13 Abbvie Inc IL-17 BINDING PROTEINS
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
US10702583B2 (en) * 2009-03-11 2020-07-07 Promedior, Inc. Treatment methods for autoimmune disorders
WO2010104959A1 (en) * 2009-03-11 2010-09-16 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2010115728A2 (en) 2009-03-30 2010-10-14 F. Hoffmann-La Roche Ag A method for avoiding glass fogging
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
SI3248610T1 (en) 2009-05-05 2024-03-29 Amgen Inc., Fgf21 mutants and uses thereof
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5784010B2 (en) 2009-06-15 2015-09-24 バイオカイン セラピューティックス リミテッド Novel chemokine-binding polypeptides that can inhibit autoimmunity, inflammation, and the course of cancer
ES2552793T3 (en) 2009-06-17 2015-12-02 Promedior Inc. SAP variants and their use
EP2445923B1 (en) 2009-06-22 2018-09-05 Amgen, Inc Refolding proteins using a chemically controlled redox state
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
IT1395137B1 (en) 2009-08-05 2012-09-05 Spider Biotech S R L NEW ANTIPATOGENIC PEPTIDES
EP2470568A2 (en) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2573915C2 (en) 2009-09-16 2016-01-27 Дженентек, Инк. Protein complexes containing superhelix and/or banding, and their use
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP5885664B2 (en) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド Screening method
BR112012008833A2 (en) 2009-10-15 2015-09-08 Abbott Lab double variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
PT3202898T (en) 2009-11-02 2018-12-28 Univ Washington Therapeutic nuclease compositions and methods
CN102648212B (en) * 2009-11-13 2014-12-03 基立福疗法公司 Von willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
CA2780763A1 (en) 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
AU2011207626B2 (en) * 2010-01-19 2015-06-18 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
JP6170675B2 (en) 2010-01-28 2017-07-26 ラプトール ファーマシューティカルズ インコーポレイテッド Method for treatment of liver injury with a receptor-associated protein (RAP) peptide-fucosidase inhibitor complex
EP2977055A1 (en) 2010-02-16 2016-01-27 Novo Nordisk A/S Factor viii fusion protein
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
KR101831459B1 (en) 2010-03-03 2018-04-04 더 유니버시티 오브 브리티시 콜롬비아 Oligomer-specific amyloid beta epitope and antibodies
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
CA2794708C (en) 2010-03-29 2021-11-16 Zymeworks Inc. Antibodies with enhanced or suppressed effector function
CN102971337B (en) 2010-04-01 2016-09-21 昂考梅德药品有限公司 FZ combines medicament and application thereof
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AR081755A1 (en) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd FORMULATION OF PROLONGED ACTION OF THE FOLICULES STIMULATING HORMONE WHERE AN IMMUNOGLOBULIN FRAGMENT, PREPARATION METHOD AND METHOD TO TREAT A SUBJECT SUFFERING A REPRODUCTIVE DISORDER ARE USED
EP2556086B1 (en) 2010-04-09 2015-03-04 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX346731B (en) 2010-04-23 2017-03-30 Genentech Inc * Production of heteromultimeric proteins.
JP2013528599A (en) 2010-05-14 2013-07-11 アムジェン インコーポレイテッド Enhanced death receptor agonist
UY33386A (en) 2010-05-14 2011-12-30 Abbott Laboratoires IL-1 UNION PROTEINS
CN102260343A (en) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 Application of recombinant human G-CSF dimer for treating nerve damage disease
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
WO2012012141A1 (en) 2010-06-30 2012-01-26 Amgen Inc. Scnn1a/tnfrsf1a fusion proteins in cancer
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
MX341579B (en) 2010-08-03 2016-08-25 Abbvie Inc * Dual variable domain immunoglobulins and uses thereof.
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
CN103298833B (en) 2010-08-14 2015-12-16 Abbvie公司 Amyloid beta associated proteins
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
ES2728282T3 (en) 2010-09-10 2019-10-23 Wyeth Llc Non-lipidated variants of ORF2086 antigens from Neisseria meningitidis
EA201370076A1 (en) 2010-09-22 2013-08-30 Амген Инк. IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION
DK3241558T3 (en) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc HIGH RESOLUTION LEPTINES
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TW201307388A (en) 2010-12-21 2013-02-16 Abbott Lab IL-1 binding proteins
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
US9315566B2 (en) 2011-01-24 2016-04-19 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
RU2018108836A (en) 2011-02-04 2019-03-14 Дженентек, Инк. Fc OPTIONS AND METHODS FOR PRODUCING THEM
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
EP2683397B1 (en) 2011-03-09 2017-08-09 CSL Behring GmbH Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2686340A2 (en) 2011-03-16 2014-01-22 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
CN103619881B (en) 2011-04-07 2017-07-28 安姆根有限公司 New EGFR associated proteins
EP2703411B1 (en) * 2011-04-25 2017-10-11 Taiho Pharmaceutical Co., Ltd. Nanoparticles containing ph-responsive peptide
CA2834626A1 (en) 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
ES2704038T3 (en) 2011-05-24 2019-03-13 Zyngenia Inc Multivalent and monovalent multispecific complexes and their uses
EP3434687B1 (en) 2011-06-10 2021-03-10 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
RU2733544C2 (en) 2011-06-17 2020-10-05 Ханми Сайенс Ко., Лтд. Conjugate containing oxintomodulin and immunoglobulin fragment, and its application
MX358726B (en) 2011-06-29 2018-09-03 Amgen Inc Predictive biomarker of survival in the treatment of renal cell carcinoma.
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
CA2842323A1 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
EP2734843A2 (en) 2011-07-18 2014-05-28 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
KR102042982B1 (en) 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
CA2842969C (en) 2011-07-25 2018-03-27 Generon (Shanghai) Corporation Ltd. Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
EP3348575A1 (en) 2011-08-16 2018-07-18 Emory University Jaml specific binding agents, antibodies, and uses related thereto
JP2014531424A (en) * 2011-08-31 2014-11-27 インディ モレキュラー，インコーポレイテッド VEGF-specific capture agents, compositions, and methods of use and manufacture
DE202012012998U1 (en) 2011-08-31 2014-06-13 Daniel Elias Bioactive, regenerative mixture for the preparation of a supplementary food
EA201490555A1 (en) 2011-09-02 2014-07-30 Эмджен Инк. PHARMACEUTICAL PRODUCT AND METHOD FOR ANALYSIS OF THE REACTION OF THE PHARMACEUTICAL PRODUCT ON THE LIGHT
TWI593708B (en) 2011-09-26 2017-08-01 諾華公司 Fusion proteins for treating metabolic disorders
CN107266577B (en) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 Improved assembly of bispecific antibodies
EP2771361A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Bispecific immunobinders directed against tnf and il-17
IN2014CN03936A (en) 2011-10-24 2015-09-04 Abbvie Inc
WO2013063298A1 (en) 2011-10-26 2013-05-02 Amgen Inc. Methods of reducing or eliminating protein modification and degradation arising from exposure to uv light
CN102516393B (en) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 Insulin-simulated peptide fusion protein and mutant and its application
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2859504A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP2794626B3 (en) 2011-12-22 2020-08-05 GlycoMimetics, Inc. E-selectin antagonist compounds
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
CN102558358A (en) * 2011-12-30 2012-07-11 张海涛 Preparation and application of human fibroblast growth factor 21 fusion protein and mutant of human fibroblast growth factor 21 fusion protein
EP2806781B1 (en) 2012-01-23 2018-03-21 Washington University Goggle imaging systems and methods
NZ625403A (en) 2012-01-27 2016-03-31 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
PL2814502T3 (en) 2012-02-15 2018-02-28 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
CA2864702A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
EP3485906A1 (en) 2012-03-09 2019-05-22 Pfizer Inc Neisseria meningitidis compositions and methods thereof
EP2831116A1 (en) 2012-03-28 2015-02-04 Amgen Inc. Dr5 receptor agonist combinations
CA2871468C (en) 2012-04-23 2021-09-21 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
EP2846822A2 (en) 2012-05-11 2015-03-18 Prorec Bio AB Method for diagnosis and treatment of prolactin associated disorders
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
BR112014032193A2 (en) 2012-06-27 2017-06-27 Hoffmann La Roche bispecific antibody production and combination determination methods, bispecific antibody, formulation and use of bispecific antibody
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
UY34905A (en) 2012-07-12 2014-01-31 Abbvie Inc IL-1 UNION PROTEINS
WO2014015148A1 (en) 2012-07-19 2014-01-23 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
WO2014060712A1 (en) * 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
TW202210507A (en) 2012-11-01 2022-03-16 美商艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
ES2748158T3 (en) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising oxyntomodulin and an immunoglobulin fragment
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
EP2935311B1 (en) * 2012-12-20 2021-03-31 Amgen Inc. Apj receptor agonists and uses thereof
WO2014110503A1 (en) * 2013-01-11 2014-07-17 Case Western Reserve University Methods and compositions for treating cancer
KR102073748B1 (en) 2013-01-31 2020-02-05 한미약품 주식회사 Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same
KR20150136061A (en) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 Administration of an anti-activin-a compound to a subject
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
WO2014133324A1 (en) * 2013-02-26 2014-09-04 한미약품 주식회사 Novel insulin analog and use thereof
EP2966092A4 (en) * 2013-03-08 2016-11-16 Taiho Pharmaceutical Co Ltd Novel peptide having 5 linked ctl epitopes
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
PT2968461T (en) 2013-03-13 2022-12-26 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CA2913155A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
ES2753419T3 (en) 2013-06-07 2020-04-08 Univ Duke Complement factor H inhibitors
US20160166660A1 (en) 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
AU2013396206B2 (en) 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
SG11201600208RA (en) 2013-07-25 2016-02-26 Novartis Ag Bioconjugates of synthetic apelin polypeptides
AP2016009021A0 (en) 2013-07-25 2016-02-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
KR20210002757A (en) 2013-09-08 2021-01-08 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
HUE043206T2 (en) * 2013-09-18 2019-08-28 Bcn Peptides Sa Cortistatin analogues for the treatment of inflammatory and/or immune diseases
WO2015057820A2 (en) * 2013-10-15 2015-04-23 Roberts S Kenny Peptide constructs and well-defined aggregates thereof
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
HUE050164T2 (en) 2013-10-21 2020-12-28 Taiho Pharmaceutical Co Ltd Novel four-ctl epitope-joined peptide
PL3063275T3 (en) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
EP3546474B1 (en) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
EP4101461A1 (en) 2014-01-09 2022-12-14 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
RU2711485C2 (en) * 2014-04-11 2020-01-17 МЕДИММЬЮН, ЭлЭлСи Conjugated compounds containing cysteine-constructed antibodies
KR20230164192A (en) 2014-05-06 2023-12-01 제넨테크, 인크. Production of heteromultimeric proteins using mammalian cells
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
US20160002326A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
KR102513050B1 (en) 2014-06-18 2023-03-29 체에스엘 베링 게엠베하 Therapy using a factor xii inhibitor in a neurotraumatic disorder
DK3164150T3 (en) 2014-07-02 2021-02-08 CSL Behring Lengnau AG MODIFIED BY WILLEBRAND FACTOR
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI802396B (en) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
US10202616B2 (en) 2014-10-15 2019-02-12 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US11813328B2 (en) 2014-10-23 2023-11-14 Amgen Inc. Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US10774323B2 (en) * 2014-12-22 2020-09-15 Lanthiopep B.V. Methods for displaying cyclic peptides on bacteriophage particles
KR102418477B1 (en) 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
WO2016118921A1 (en) 2015-01-24 2016-07-28 Abbvie, Inc. Compositions and methods for treating psoriatic arthritis
WO2016123570A1 (en) * 2015-01-30 2016-08-04 University Of Utah Research Foundation Dimeric collagen hybridizing peptides and methods of using
MX2017010705A (en) 2015-02-19 2017-12-04 Pfizer Neisseria meningitidis compositions and methods thereof.
EP3265491A1 (en) 2015-03-03 2018-01-10 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
KR102458219B1 (en) * 2015-03-05 2022-10-24 피터 운드 트라우들 앵겔호른-스티프텅 주르 푀르데룽 데르 레벤스위센샤프텐 A system for presenting peptides on the cell surface
EP3281010B1 (en) 2015-04-10 2020-12-30 The Regents of The University of California Methods of determining patient populations amenable to immunomodulatory treatment of cancer
WO2016176427A1 (en) 2015-04-30 2016-11-03 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
WO2016179350A1 (en) 2015-05-06 2016-11-10 Washington University Compounds having rd targeting motifs and methods of use thereof
RU2017145014A (en) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг DIFFERENT POLYPEPTIDES OF THE VILLEBRAND VON FACTOR FOR THE TREATMENT OF HEMOPHILIA
BR112017024714A2 (en) 2015-05-22 2018-09-11 Csl Behring Recombinant Facility Ag methods for preparing modified von willebrand factor
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CN107921143B (en) 2015-06-15 2021-11-19 安吉奥开米公司 Method for treating leptomeningeal carcinomatosis
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
MA42821A (en) 2015-09-15 2018-07-25 Amgen Inc TETRAVALENT TETRASPECIFIC AND BISPECIFIC BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
JP7002446B2 (en) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー CD3 binding polypeptide
CA3000697A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
SI3356411T1 (en) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
US10975131B2 (en) 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
KR101826792B1 (en) * 2015-10-29 2018-02-09 주식회사 와이바이오로직스 Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog
AU2016372026A1 (en) * 2015-12-15 2018-06-21 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
EP3390364B1 (en) 2015-12-17 2020-07-15 Biokine Therapeutics Ltd. Small molecules for inhibiting chemokine activity and/or cancer cells growth
WO2017103931A1 (en) 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
CN108472338B (en) 2016-01-07 2022-12-30 康诺贝林伦瑙有限公司 Mutant truncated von Willebrand factor
CA3019851A1 (en) 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
EP3424948B1 (en) * 2016-04-07 2021-07-28 Industry-University Cooperation Foundation Hanyang University ERICA Campus Vascular endothelial growth factor targeting peptide-elastin fusion polypeptide and self-assembling nanostructure, which are for inhibiting angiogenesis
JPWO2017179647A1 (en) * 2016-04-14 2019-02-21 Ｔａｏヘルスライフファーマ株式会社 Amyrospheroid (ASPD) binding inhibitory peptide, and evaluation and screening method
JP2019515677A (en) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー Antibody conjugates and methods of making and using the same
PE20190177A1 (en) 2016-06-08 2019-02-01 Abbvie Inc ANTI-B7-H3 ANTIBODIES AND ANTIBODY AND DRUG CONJUGATES
JP7308034B2 (en) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー Optimized double nuclease fusions and methods
EP3487867A2 (en) 2016-07-22 2019-05-29 Amgen Inc. Methods of purifying fc-containing proteins
CN106279437B (en) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759697B (en) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 Method for producing fusion protein
MA46466A (en) 2016-10-06 2019-08-14 Amgen Inc PHARMACEUTICAL FORMULATIONS OF REDUCED VISCOSITY PROTEINS
WO2018079702A1 (en) 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ Lactoferrin/albumin fusion protein and production method therefor
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
TW201828975A (en) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 Truncated von Willebrand factor polypeptides for treating hemophilia
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
WO2018102777A1 (en) * 2016-12-01 2018-06-07 University Of South Florida Peptibodies, compositions thereof, and methods of treating atrial fibrillation
US20190382462A1 (en) 2017-01-13 2019-12-19 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer Neisseria meningitidis compositions and methods thereof
JP2020511513A (en) 2017-03-23 2020-04-16 ハンミ ファーマシューティカル カンパニー リミテッド Insulin analog conjugates having reduced binding to the insulin receptor and uses thereof
BR112019017329A2 (en) * 2017-04-03 2020-04-14 Hoffmann La Roche immunoconjugates, one or more polynucleotides and vectors, methods for the production of an immunoconjugate, treatment of a disease and for the stimulation of the immune system, composition, use of the immunoconjugate, invention and uses of the composition
CN116375876A (en) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 Bispecific antibodies that specifically bind PD1 and LAG3
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
AU2018304585B2 (en) 2017-07-20 2023-07-06 Alligator Bioscience Ab Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
AU2018306329A1 (en) 2017-07-26 2020-02-13 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
WO2019028012A2 (en) 2017-07-31 2019-02-07 Dana-Farber Cancer Institute, Inc. Methods of using pembrolizumab and trebananib
JP2020529986A (en) 2017-08-04 2020-10-15 アムジエン・インコーポレーテツド Cysteine-MAB conjugation method
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology Multiple specificity binders of cxc chemokines and uses thereof
CN111344410B (en) 2017-08-17 2023-09-15 济世易为生物有限公司 Method for purifying glycosylated proteins from host cell galectins and other contaminants
SG11202001311VA (en) 2017-08-22 2020-03-30 Sanabio Llc Soluble interferon receptors and uses thereof
KR20200101954A (en) 2017-12-19 2020-08-28 메사추세츠 인스티튜트 오브 테크놀로지 Antigen-adjuvant coupling reagents and methods of use
EP3777894A4 (en) * 2018-03-30 2022-04-06 Hanmi Pharm. Co., Ltd. Brain-targeting, long-acting protein conjugate, preparation method therefor, and composition comprising same
BR112021007611A2 (en) 2018-10-23 2021-07-27 Amgen Inc. automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
AU2019373090B2 (en) 2018-10-31 2023-05-25 The University Of Sydney Compositions and methods for treating viral infections
JP2022516635A (en) 2019-01-04 2022-03-01 リゾルブ セラピューティクス， エルエルシー Treatment of Sjogren's disease with a nuclease fusion protein
EP3908307A4 (en) * 2019-01-07 2022-10-12 Cenna Biosciences Inc. Novel peptides and uses thereof
JP2022523295A (en) 2019-01-25 2022-04-22 ヤンセン ファーマシューティカ エヌ．ベー． How to mitigate the toxic effects of blisters and caustic gases
MX2021008928A (en) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure.
MA54820A (en) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv METHODS OF MITIGATING LIVER DAMAGE AND PROMOTING HYPERTROPHY, LIVER REGENERATION AND LIVER CELL TRANSPLANTATION IN CONJUNCTION WITH RADIATION THERAPY AND/OR RADIOMIMETIC TREATMENTS
KR20210124308A (en) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. Anti-GAL3 antibodies and uses thereof
WO2020168315A1 (en) 2019-02-15 2020-08-20 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
EP3941580A1 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
EP3941581A2 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. Multivalent d-peptidic compounds for target proteins
KR20220009442A (en) 2019-05-15 2022-01-24 아론바이오 리미티드 Small molecules for cancer treatment, inhibition of chemokine activity and/or induction of cell death
KR20220009984A (en) 2019-05-17 2022-01-25 유니베르시태트 취리히 Haptoglobin for use in the treatment of secondary neurological adverse events after hemorrhagic stroke
AU2020283890A1 (en) 2019-05-30 2021-12-16 Amgen Inc. Engineering the hinge region to drive antibody dimerization
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3990493A1 (en) 2019-06-28 2022-05-04 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
EP3994162A1 (en) 2019-07-04 2022-05-11 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
AU2020329217A1 (en) 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
JP2022553813A (en) 2019-11-08 2022-12-26 アムジエン・インコーポレーテツド Engineering charge-pair mutations for pairing hetero-IgG molecules
JP2023500953A (en) 2019-11-11 2023-01-11 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Polypeptides for inducing tolerance to factor VIII
EP4072598A4 (en) 2019-12-13 2024-02-21 Washington University St Louis Near infrared fluorescent dyes, formulations and related methods
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
CA3164385A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
WO2021158469A1 (en) 2020-02-03 2021-08-12 Amgen Inc. Multivariate bracketing approach for sterile filter validation
WO2022006153A1 (en) 2020-06-29 2022-01-06 Resolve Therapeutics, Llc Treatment of sjogren's syndrome with nuclease fusion proteins
EP4200338A1 (en) 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
EP4225786A2 (en) 2020-10-07 2023-08-16 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
JP2023548595A (en) 2020-11-10 2023-11-17 アムジエン・インコーポレーテツド Novel linkers for multispecific antigen binding domains
US20240000908A1 (en) 2020-11-20 2024-01-04 Csl Behring Gmbh Method for Treating Antibody-Mediated Rejection
MX2023006426A (en) 2020-12-01 2023-07-17 Aptevo Res And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies.
CA3200462A1 (en) 2020-12-18 2022-06-23 Sebastian Damerow Methods for the purification of refolded fc-peptide fusion protein
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
EP4284407A1 (en) 2021-02-01 2023-12-06 CSL Behring AG Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
CN117651714A (en) 2021-04-20 2024-03-05 美国安进公司 Balanced charge distribution in electrostatic steering of chain pairing in multispecific and monovalent IgG molecule assembly
CA3217518A1 (en) 2021-05-07 2022-11-10 Rebecca Butcher Expression system for producing a recombinant haptoglobin (hp) beta chain
WO2022246244A1 (en) 2021-05-21 2022-11-24 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
CA3234340A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
TW202323281A (en) 2021-10-14 2023-06-16 美商泰尼歐生物公司 Mesothelin binding proteins and uses thereof
AR127458A1 (en) 2021-10-27 2024-01-24 Amgen Inc PREDICTION BASED ON DEEP LEARNING USING SPECTROSCOPY
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof
WO2023180525A1 (en) 2022-03-24 2023-09-28 Richter Gedeon Nyrt. Method for the manufacture of biopharmaceuticals
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
WO1996040772A2 (en) * 1995-06-07 1996-12-19 Ortho Pharmaceutical Corporation Agonist peptide dimers
WO1997028828A1 (en) * 1996-02-09 1997-08-14 Amgen Boulder Inc. Composition comprising interleukin-1 inhibitor and controlled release polymer
WO1997044453A1 (en) * 1996-05-07 1997-11-27 Genentech, Inc. Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
WO1998024477A1 (en) * 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US5767234A (en) * 1994-02-02 1998-06-16 Affymax Technologies, N.V. Peptides and compounds that bind to the IL-1 receptor
WO1998031820A1 (en) * 1997-01-18 1998-07-23 Boryung Pharmaceutical Co., Ltd. A CTLA4-Ig FUSION PROTEIN HAVING HIGH TITER
WO1998046257A1 (en) * 1997-04-17 1998-10-22 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4760067A (en) * 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
DE3175151D1 (en) 1980-05-21 1986-09-25 Teijin Ltd Reactive polymer and process for the preparation thereof
US4560649A (en) * 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (en) * 1982-03-15 1995-06-05 味の素株式会社 Cancer therapeutic agent containing interleukin-2
ATE37983T1 (en) 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4966888A (en) * 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (en) * 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE470099B (en) * 1984-05-17 1993-11-08 Jerker Porath Sulfone activated thioether adsorbents for separation of eg protein
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
CA1283661C (en) 1984-06-20 1991-04-30 Franz Jansen Imidazolides, process for their preparation and application as intermediates for the synthesis of cytotoxic conjugates
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
SE454885B (en) * 1984-10-19 1988-06-06 Exploaterings Ab Tbf POLYMER COATED PARTICLES WITH IMMOBILIZED METAL ZONES IN ITS SURFACE PROCEDURES FOR PRODUCING THEREOF
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
DE3675588D1 (en) * 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5359032A (en) * 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DE68926888T2 (en) 1988-01-22 1997-01-09 Zymogenetics Inc Process for the production of secreted receptor analogs
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5359037A (en) * 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
AU4660789A (en) 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
EP1201757A3 (en) 1988-12-22 2002-09-11 Genentech, Inc. Method for preparing water soluble polypeptides
US5093475A (en) * 1988-12-22 1992-03-03 Xoma Corporation Hindered linking agents derived from 2-iminothiolanes and methods
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5116964A (en) † 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3922089A1 (en) * 1989-05-09 1990-12-13 Basf Ag NEW PROTEINS AND THEIR PRODUCTION
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
DE10399023I2 (en) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DK0502956T3 (en) * 1989-11-29 1997-10-20 Amgen Boulder Inc Preparation of a Recombinant Human Interleukin-1 Inhibitor.
WO1991011497A1 (en) † 1990-01-23 1991-08-08 MERCK Patent Gesellschaft mit beschränkter Haftung Liquid crystalline medium
US5136021A (en) * 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5349053A (en) † 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
EP0714912B1 (en) 1990-07-17 2002-09-25 The Board Of Regents Of The University Of Oklahoma GMP-140 ligand
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5569779A (en) * 1991-12-23 1996-10-29 Albemarle Corporation Polyfunctional michael addition products
DE69312700T2 (en) 1992-04-14 1998-02-19 Cornell Res Foundation Inc MACROMOLECULES BASED ON DENDRITIC POLYMERS AND METHOD FOR THE PRODUCTION THEREOF
CA2118508A1 (en) † 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE311895T1 (en) 1992-05-26 2005-12-15 Immunex Corp NEW CYTOKINE THAT BINDS CD30
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
AU5098393A (en) * 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
NZ247231A (en) * 1993-03-23 1994-10-26 Holyoake Ind Ltd Diffuser for air conditioning system; outlet air direction thermostatically controlled
EP0710121B1 (en) * 1993-07-30 2000-10-11 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5998172A (en) † 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
PL178384B1 (en) 1994-02-14 2000-04-28 Univ Washington Haemopoesive protein as well as method of and materials for obtaining same
WO1995026746A1 (en) 1994-03-31 1995-10-12 Amgen Inc. Compositions and methods for stimulating megakaryocyte growth and differentiation
CN1110557C (en) † 1994-05-06 2003-06-04 古斯达威罗斯研究所 LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
US6184205B1 (en) † 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
AU700605B2 (en) 1994-12-07 1999-01-07 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
AU3204895A (en) 1995-02-01 1996-08-21 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69637473T2 (en) 1995-06-07 2009-05-07 Glaxo Group Ltd., Greenford PEPTIDES AND COMPOUNDS BINDING ON A THROMBOPOIETIN RECEPTOR
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO1996040189A1 (en) 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a receptor
IL118524A (en) 1995-06-19 2004-02-19 Akzo Nobel Nv Peptides and pharmaceutical compositions containing them useful in a peptide tolerance therapy
US5955574A (en) † 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
WO1997008553A1 (en) 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5798246A (en) 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
EP0906419A2 (en) 1996-03-28 1999-04-07 Chiron Corporation Peptide ligands of the urokinase receptor
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
WO1997043316A1 (en) † 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
EP0911393B1 (en) 1996-06-07 2007-01-10 Takeda Pharmaceutical Company Limited Peptide having cortistatin or somatostatin activity, process for the production of the same, and use of the same
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
CA2265484C (en) 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
JP2001512560A (en) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ Methods and means for the selection of peptides and proteins with specific affinity for a target
US5958703A (en) * 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
KR100937550B1 (en) 1996-12-20 2010-01-19 암젠 인코포레이티드 Ob fusion protein compositions and process for producing such protein
US5955431A (en) 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
EP0998577B1 (en) 1997-07-24 2004-10-27 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6238667B1 (en) 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
AU9790798A (en) 1997-10-06 1999-04-27 Millennium Pharmaceuticals, Inc. Signal peptide containing proteins and uses therefor
EA200000409A1 (en) 1997-10-10 2000-10-30 Сайтовиэ, Инк. Compounds, pharmaceutical compositions, methods for inhibiting cell death in a cell or tissue, methods of treating or REDUCE cell death, treatment or prophylaxis of polycystic kidney or anemia / erythropoiesis in an animal way to protect an organ or tissue of mammals from extinction CELLS, METHOD FOR REDUCTION OR PREVENTION CELL DEFENSE IN ORGAN OR TREATMENT OF DONOR AFTER THEIR TRANSPLANTATION, THE WAY TO REDUCE OR PREVENT THE DESTRUCTION OF SPERM OR EGGS
JP2001522817A (en) 1997-11-07 2001-11-20 コンジュケム，インコーポレーテッド Novel conjugate of opioid and endogenous carrier
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1135153B1 (en) * 1998-11-20 2005-04-27 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
AU2880400A (en) * 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
DE60028970T2 (en) † 1999-07-02 2007-02-15 Genentech Inc., San Francisco AT HER2 BINDING PEPTIDE COMPOUNDS
WO2001002440A1 (en) † 1999-07-02 2001-01-11 Genentech, Inc. Fusion peptides comprising a peptide ligand domain and a multimerization domain
WO2001085782A2 (en) * 2000-02-11 2001-11-15 Amgen Inc. Fusion receptor from tnf family
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1575499A2 (en) 2002-06-28 2005-09-21 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2005259537A1 (en) * 2004-06-25 2006-01-12 Licentia, Ltd. Tie receptor and tie ligand materials and methods for modulating female fertility
NZ556029A (en) * 2004-12-21 2010-04-30 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5767234A (en) * 1994-02-02 1998-06-16 Affymax Technologies, N.V. Peptides and compounds that bind to the IL-1 receptor
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
WO1996040772A2 (en) * 1995-06-07 1996-12-19 Ortho Pharmaceutical Corporation Agonist peptide dimers
WO1997028828A1 (en) * 1996-02-09 1997-08-14 Amgen Boulder Inc. Composition comprising interleukin-1 inhibitor and controlled release polymer
WO1997044453A1 (en) * 1996-05-07 1997-11-27 Genentech, Inc. Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
WO1998024477A1 (en) * 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
WO1998031820A1 (en) * 1997-01-18 1998-07-23 Boryung Pharmaceutical Co., Ltd. A CTLA4-Ig FUSION PROTEIN HAVING HIGH TITER
WO1998046257A1 (en) * 1997-04-17 1998-10-22 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. BROCKS ET AL.: "A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells.", IMMUNOTECHNOLOGY, vol. 3, no. 3, October 1997 (1997-10-01), Amsterdam, The Netherlands, pages 173 - 184, XP002147314 *
D. JOHNSON ET AL.: "Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1.", BIOCHEMISTRY, vol. 37, no. 11, 1998, Washington, DC, USA, pages 3699 - 3710, XP002147315 *
H. LOETSCHER ET AL.: "Efficacy of a chimeric TNFR-IgG fusion protein to inhibit TNF activity in animal models of septic shock.", INTERNATIONAL CONGRESS SERIES, vol. 2, 1993, Amsterdam, The Netherlands, pages 455 - 462, XP002067659 *
S. CWIRLA ET AL.: "Peptide agonists of the thrombopoietin receptor as potent as the natural cytokine.", SCIENCE, vol. 276, no. 5319, 13 June 1997 (1997-06-13), Washington, DC, USA, pages 1696 - 1699, XP002142424 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8734791B2 (en) 2002-03-01 2014-05-27 Xencor, Inc. Optimized fc variants and methods for their generation
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093359B2 (en) 2002-09-27 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US9193798B2 (en) 2002-09-27 2015-11-24 Xencor, Inc. Optimized Fc variants and methods for their generation
US9353187B2 (en) 2002-09-27 2016-05-31 Xencor, Inc. Optimized FC variants and methods for their generation
US8858937B2 (en) 2002-09-27 2014-10-14 Xencor, Inc. Optimized Fc variants and methods for their generation
US8809503B2 (en) 2002-09-27 2014-08-19 Xencor, Inc. Optimized Fc variants and methods for their generation
US8383109B2 (en) 2002-09-27 2013-02-26 Xencor, Inc. Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8735545B2 (en) 2003-03-03 2014-05-27 Xencor, Inc. Fc variants having increased affinity for fcyrllc
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US8324351B2 (en) 2004-11-12 2012-12-04 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8338574B2 (en) 2004-11-12 2012-12-25 Xencor, Inc. FC variants with altered binding to FCRN
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US9574006B2 (en) 2005-10-06 2017-02-21 Xencor, Inc. Optimized anti-CD30 antibodies
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US8410051B2 (en) 2008-06-04 2013-04-02 Amgen Inc. FGF21 mutants and uses thereof
US8642546B2 (en) 2008-06-04 2014-02-04 Amgen Inc. FGF21 mutant fusion polypeptides and uses thereof
US9273106B2 (en) 2008-06-04 2016-03-01 Amgen Inc. FGF mutants with reduced proteolysis and aggregation
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9493577B2 (en) 2009-12-07 2016-11-15 Amgen Inc. Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity

Also Published As

Publication number Publication date
KR100753305B1 (en) 2007-08-29
CN100384880C (en) 2008-04-30
US20040087778A1 (en) 2004-05-06
BG105461A (en) 2003-04-30
KR20070050977A (en) 2007-05-16
US20040053845A1 (en) 2004-03-18
ES2299278T3 (en) 2008-05-16
HK1042097B (en) 2008-04-03
AU2004200687C1 (en) 2009-03-26
CA2347131C (en) 2012-11-27
NO331733B1 (en) 2012-03-12
EA005404B1 (en) 2005-02-24
CN1721447A (en) 2006-01-18
JP2007084555A (en) 2007-04-05
PL366080A1 (en) 2005-01-24
IL142365A (en) 2013-02-28
US20040057953A1 (en) 2004-03-25
HK1090932A1 (en) 2007-01-05
AU767725C (en) 2000-05-15
EP1144454B1 (en) 2007-12-12
PT1144454E (en) 2008-02-08
KR100753304B1 (en) 2007-08-29
AU2004200690A1 (en) 2004-03-18
SI1144454T1 (en) 2008-04-30
US7189827B2 (en) 2007-03-13
CN1746189A (en) 2006-03-15
AU2004200690C1 (en) 2009-04-09
MXPA01003873A (en) 2003-10-14
EP1144454A2 (en) 2001-10-17
ES2299278T5 (en) 2013-04-03
SK5252001A3 (en) 2002-12-03
CN1310948C (en) 2007-04-18
SK287037B6 (en) 2009-10-07
AU2004200690B2 (en) 2007-05-10
HK1042097A1 (en) 2002-08-02
JP2007091747A (en) 2007-04-12
DE69937752D1 (en) 2008-01-24
JP2007091746A (en) 2007-04-12
CN1746190A (en) 2006-03-15
ZA200102753B (en) 2002-06-11
US7169905B2 (en) 2007-01-30
HUP0203506A2 (en) 2003-02-28
CN1781947A (en) 2006-06-07
JP2007084558A (en) 2007-04-05
DE69937752T3 (en) 2013-02-28
JP2007084557A (en) 2007-04-05
EP1144454B2 (en) 2012-12-12
US20070049532A1 (en) 2007-03-01
CN1331701A (en) 2002-01-16
AU767725B2 (en) 2003-11-20
HUP0203506A3 (en) 2012-09-28
AU2004200687B2 (en) 2007-05-10
AU1232200A (en) 2000-05-15
YU25901A (en) 2005-07-19
CZ304242B6 (en) 2014-01-22
CY1107881T1 (en) 2013-06-19
CN1781946A (en) 2006-06-07
PL211164B1 (en) 2012-04-30
US20040071712A1 (en) 2004-04-15
KR20070050978A (en) 2007-05-16
EA200100464A1 (en) 2002-10-31
US6660843B1 (en) 2003-12-09
US20040044188A1 (en) 2004-03-04
HU229485B1 (en) 2014-01-28
NZ510888A (en) 2004-01-30
AU2004200687A1 (en) 2004-03-18
US7186810B2 (en) 2007-03-06
IL142365A0 (en) 2002-03-10
JP2007084556A (en) 2007-04-05
CN1908014A (en) 2007-02-07
DK1144454T4 (en) 2013-01-14
DE69937752T2 (en) 2008-12-24
NO20011963L (en) 2001-06-21
CA2347131A1 (en) 2000-05-04
JP2007089586A (en) 2007-04-12
NO20011963D0 (en) 2001-04-20
NZ528882A (en) 2005-06-24
WO2000024782A2 (en) 2000-05-04
DK1144454T3 (en) 2008-05-05
RS51852B (en) 2012-02-29
ATE380828T1 (en) 2007-12-15
JP2003512011A (en) 2003-04-02
JP2007105044A (en) 2007-04-26
BR9914708A (en) 2002-07-16
US7166707B2 (en) 2007-01-23
CN1781945A (en) 2006-06-07
BG65721B1 (en) 2009-08-31
KR20010099706A (en) 2001-11-09
SI1144454T2 (en) 2013-04-30
KR100753303B1 (en) 2007-08-29
CN100384879C (en) 2008-04-30

Similar Documents

Publication Publication Date Title
WO2000024782A3 (en) Modified peptides, comprising an fc domain, as therapeutic agents
WO2001083525A3 (en) Modified peptides, comprising an fc domain, as therapeutic agents
JP2004501875A (en) Tripeptide prodrug compounds
MX2007003320A (en) Modified fc molecules.
JP2004510702A (en) Prodrug compounds having isoleucine
ATE342358T1 (en) NEW HUMAN DELTA3 COMPOSITION AND THEIR THERAPEUTIC AND DIAGNOSTIC USES
Braun et al. Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate
JP2011137044A (en) Fibrin/fibrinogen-binding conjugate
US20090252703A1 (en) Use of alcohol co-solvents to improve pegylation reaction yields
JP2005506340A5 (en)
CA2352286A1 (en) Intracellular targeted delivery of compounds by 70 kd heat shock protein
WO1998037100A3 (en) Therapeutic use of the smr1 protein and active derivatives thereof
AU2001293055A1 (en) A fibrin/fibrinogen-binding conjugate
US20030186890A1 (en) Amphipathic linear peptides and formulations containing said peptides
EP1452543A3 (en) RGD (ARG-GLY-ASP) coupled to (neuro)peptides
WO1999037669A1 (en) PEPTIDES WITH β1 INTEGRIN SUBUNIT DEPENDENT CELL ADHESION MODULATING ACTIVITY

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-259/01

Country of ref document: YU

Ref document number: 99814727.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 12322

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 510888

Country of ref document: NZ

Ref document number: 142365

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001/02753

Country of ref document: ZA

Ref document number: 200102753

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2347131

Country of ref document: CA

Ref document number: 2347131

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-1323

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/003873

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12322/00

Country of ref document: AU

Ref document number: 5252001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 578351

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017004982

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999971003

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1999 105461

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200100464

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999971003

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017004982

Country of ref document: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: PV2001-1323

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 12322/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999971003

Country of ref document: EP